Lyell Immunopharma, Inc.

Historical 13F Holders

Symbol
LYEL
CUSIP
55083R104
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 55083R104 since 12/18/2024, largest first.

Filer % of Class Filed
ARCH Venture Fund IX, L.P. 13G/A
13.1% 2/14/2025
Event 12/31/2024
Foresite Capital Fund IV, L.P. 13G/A
9.2% 5/15/2025
Event 3/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
Explore Investments LLC/DE 13G
Amended under CUSIP 55083R203 on 5/8/2026
5.4% 8/19/2025
Event 7/25/2025
BlackRock, Inc. 13G/A 4.5% 2/5/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 1 692 k $9.72 M
2026 Q1 1 692 k $13.9 M
2025 Q4 1 692 k $21.3 M
2025 Q3 2 650 k $10.6 M
2025 Q2 6 2.44 M $21.6 M
2025 Q1 116 152 M $81.8 M
2024 Q4 110 150 M $95.9 M
2024 Q3 121 129 M $177 M
2024 Q2 125 134 M $195 M
2024 Q1 133 135 M $301 M
2023 Q4 125 133 M $258 M
2023 Q3 110 123 M $180 M
2023 Q2 102 122 M $389 M
2023 Q1 104 118 M $278 M
2022 Q4 101 125 M $435 M
2022 Q3 95 112 M $824 M
2022 Q2 77 106 M $689 M
2022 Q1 83 99.7 M $504 M
2021 Q4 80 85.6 M $662 M
2021 Q3 63 82.5 M $1.22 B
2021 Q2 53 79.7 M $1.29 B